Comparable stake leader
Knight Therapeutics Inc.
SEC ownership of Synergy CHC Corp.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001562733.
Disclosed value leader
Jack Ross
Comparable rows
16/17
Latest evidence
29 Jun 2026
- Public ticker
- SNYR on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Knight Therapeutics Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
16 of 17
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Knight Therapeutics Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
29 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001562733
- Issuer location
- Westbrook, ME
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Synergy CHC Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Knight Therapeutics Inc.
Disclosed value leader
Jack Ross
Comparable rows
16/17
Latest evidence
29 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
1 rows are not safely comparable across share classes.
13D/G row: Knight Therapeutics Inc.
Showing 1-8 of 17 holder rows.
Quick read
Knight Therapeutics Inc. leads the comparable SEC ownership view at 20%.
16 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Knight Therapeutics Inc.'s linked filing trail.
Comparable ownership
Top 5
Knight Therapeutics Inc.
20%
Jack Ross
50%
Nitin Kaushal
3.2%
Teresa Brigid Thompson
0.27%
GRATIA CAPITAL, LLC
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Knight Therapeutics Inc. |
3/4/5
13D/G
10%+ Owner
|
20%
from 13D/G
|
$6,020,347
1,911,414 shares
mixed-class rows
|
— | 11 Jun 2025 |
| Jack Ross |
3/4/5
CEO and Chairman, Director, 10%+ Owner
|
50%
|
$15,240,601
4,795,757 shares
|
— | 29 Jun 2026 |
| Nitin Kaushal |
3/4/5
Director
|
3.2%
|
$353,930
306,433 shares
|
— | 21 Apr 2026 |
| Teresa Brigid Thompson |
3/4/5
Director
|
0.27%
|
$29,826
25,824 shares
|
— | 21 Apr 2026 |
| GRATIA CAPITAL, LLC |
13F
Company
|
5.7%
|
$709,500
550,000 shares
|
— | 31 Mar 2026 |
| HEARTLAND ADVISORS INC |
13F
Company
|
5.7%
|
$709,500
550,000 shares
|
— | 31 Mar 2026 |
| SANDERS MORRIS HARRIS LLC |
13F
Company
|
4.3%
|
$535,933
415,452 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.93%
|
$115,803
89,770 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to Synergy CHC Corp.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Jack Ross
Net 12M change
$0
Latest report
29 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jack Ross | CEO and Chairman, Director, 10%+ Owner | $15,240,601 | Mixed | 29 Jun 2026 | ||
| Knight Therapeutics Inc. | 10%+ Owner | $6,020,347 | Mixed | 11 Jun 2025 | ||
| James Paul SoRelle | Director | $442,390 | Mixed | 22 Oct 2024 | ||
| Nitin Kaushal | Director | $353,930 | Mixed | 21 Apr 2026 | ||
| Teresa Brigid Thompson | Director | $29,826 | Mixed | 21 Apr 2026 | ||
| Scott Woodburn | Director | Mixed | 22 Oct 2024 | |||
| Alfred Baumeler | President, Director | Mixed | 29 Jun 2026 | |||
| Jaime Fickett | Chief Financial Officer | Mixed | 29 Jun 2026 | |||
| Stacy B. McLaughlin | Chief Financial Officer | Mixed | 22 Oct 2024 |
Recent insider transactions for Synergy CHC Corp.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Alfred Baumeler | SNYR | Stock Option (right to buy) | Disposed to Issuer | -100% | -150,000 | 0 | 29 Jun 2026 | Direct | ||
| Alfred Baumeler | SNYR | Stock Option (right to buy) | Award | 150,000 | 150,000 | 29 Jun 2026 | Direct | |||
| Jaime Fickett | SNYR | Stock Option (right to buy) | Disposed to Issuer | -100% | -150,000 | 0 | 29 Jun 2026 | Direct | ||
| Jaime Fickett | SNYR | Stock Option (right to buy) | Award | 150,000 | 150,000 | 29 Jun 2026 | Direct | |||
| Jack Ross | SNYR | Stock Option (right to buy) | Disposed to Issuer | -100% | -750,000 | 0 | 29 Jun 2026 | By Kenek Brands Inc. | ||
| Jack Ross | SNYR | Stock Option (right to buy) | Award | 750,000 | 750,000 | 29 Jun 2026 | By Kenek Brands Inc. | |||
| Nitin Kaushal | SNYR | Common Stock, par value $0.00001 per share | Award | 306,433 | 306,433 | 21 Apr 2026 | Direct | |||
| Teresa Brigid Thompson | SNYR | Common Stock, par value $0.00001 per share | Award | 25,824 | 25,824 | 21 Apr 2026 | Direct | |||
| Alfred Baumeler | SNYR | Stock option (right to buy) | Award | 150,000 | 150,000 | 18 Sep 2025 | Direct | |||
| Jaime Fickett | SNYR | Stock option (right to buy) | Award | 150,000 | 150,000 | 18 Sep 2025 | Direct | |||
| Jack Ross | SNYR | Stock option (right to buy) | Award | 750,000 | 750,000 | 18 Sep 2025 | By Kenek Brands Inc. |
* marks a reported price that did not pass the local price check.